Quanli Gao
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC (NCT05878028) | Quanli Gao | 2022-09-16 |
| L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma (NCT04924413) | Quanli Gao | 2021-07-01 |
| The Immune Assessment of PD-1 Antibody Therapy in Tumor (NCT06693440) | Quanli Gao | 2021-07-01 |
Track Quanli Gao automatically
Every clearance here is in the API, with alerts when new ones post.